Inventiva Reports Q1 Financials, Confirms Limited Cash Runway into Q1 2027
IVA sits 81% above its 52-week low of $2.854 on light trading volume (0.4× avg).
Summary
Inventiva S.A. reported its first-quarter 2026 financial results, showing €196.5 million in cash and deposits, which is estimated to fund operations only until mid-Q1 2027 without additional financing.
Key Events · Financing and Capital Events · IVA
-
Q1 2026 Financials Reported
Inventiva reported €75.0 million in cash and cash equivalents and €121.5 million in short-term deposits as of March 31, 2026, totaling €196.5 million.
-
Limited Cash Runway Confirmed
The company estimates its current liquid assets will finance operations only until the middle of the first quarter of 2027.
-
Potential Warrant Proceeds
The exercise of Tranche 3 warrants could provide up to €116.0 million, potentially extending the cash runway to mid-Q3 2027, though this is not guaranteed.
-
No Revenue Generated
Inventiva reported no revenues for Q1 2026, consistent with the prior year.
Analysis · IVA · Life Sciences
This filing provides critical updated financial details following previous disclosures of a going concern uncertainty and severe financial distress. The company's current cash and short-term deposits of €196.5 million are projected to last only until the middle of the first quarter of 2027. While potential warrant exercises could provide up to €116.0 million and extend this to mid-Q3 2027, this is not guaranteed. The limited runway highlights the urgent need for additional financing to continue operations, directly impacting the company's long-term viability.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVA was trading at $5.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.85 to $7.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.